The global extracellular matrix patches market size was valued at USD 28.5 million in 2022 and is projected to reach USD 51.8 million by 2030, growing at a CAGR of 7.8% from 2023 to 2030. Market growth is primarily driven by the rising incidence of congenital heart disease (CHD) and trauma-related injuries, both of which often require repair and reconstruction procedures where ECM patches play a vital role.

According to the Centers for Disease Control and Prevention (CDC) 2022 report, approximately 18.2 million people in the U.S. were diagnosed with coronary artery disease, with nearly 70% undergoing surgical interventions. In addition, around 40,000 neonates are born each year in the U.S. with congenital heart disease (CHD), further underscoring the critical need for effective repair and reconstruction solutions such as ECM patches.

Beyond cardiovascular applications, the increasing adoption of ECM in hernia and pelvic reconstruction surgeries is also boosting market demand. Abdominal wall hernia repair is one of the most common surgical procedures globally. For example, according to Medscape, over 1 million abdominal wall hernia surgeries are performed annually in the U.S. alone. To meet this demand, several companies are investing in the development of ECM products tailored for hernia and pelvic floor reconstructions. A notable example is Aroa Biosurgery, which in April 2021 launched Myriad Morcells, a morcellized format of Myriad Matrix, designed for soft tissue repair. The product received U.S. FDA clearance on April 6, 2021, marking an important milestone in the company’s expansion within the regenerative medicine space.

Additionally, technological advancements in ECM patches designed for soft tissue repair and wound healing are further driving market growth. Innovations are focusing on enhancing ease of use, biological performance, and clinical outcomes. For instance, AltiPly, developed by Aziyo Biologics, is a ready-to-use ECM patch that does not require rehydration and can be stored at room temperature, simplifying surgical handling. It is widely applied in the treatment of venous leg ulcers, diabetic foot ulcers, and pressure wounds. AltiPly’s proprietary processing technology improves growth factor levels, thereby accelerating tissue regeneration and enhancing the healing process.

Key Market Trends & Insights:

• In 2022, North America dominated the extracellular matrix (ECM) patches market, accounting for a significant 48.0% revenue share. This strong regional position can be attributed to the high prevalence of cardiovascular diseases, congenital heart defects, and trauma-related injuries, along with advanced healthcare infrastructure and favorable reimbursement policies. Additionally, the presence of leading market players and ongoing technological innovations in ECM products further supported North America’s leadership in the global market.

• When analyzed by application, the soft tissue repair segment held the largest share in 2022, contributing 28.0% of the total revenue. The dominance of this segment is due to the increasing adoption of ECM patches in procedures involving hernia repair, wound healing, and pelvic reconstruction. Rising surgical volumes, coupled with the ability of ECM patches to promote natural tissue regeneration, have significantly boosted their demand in soft tissue applications.

• Based on raw materials, the porcine-derived ECM patches segment led the market in 2022, capturing 40.0% of the revenue share. Porcine tissues are widely utilized because of their structural similarity to human tissue, biocompatibility, and proven clinical effectiveness in regenerative applications. Their versatility in cardiovascular repair, soft tissue reconstruction, and wound management has contributed to their widespread use and strong market share.

Order a free sample PDF of the Extracellular Matrix Patches Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2022 Market Size: USD 28.5 Million

• 2030 Projected Market Size: USD 51.8 Million

• CAGR (2023-2030): 7.8%

• North America: Largest market in 2022

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Market players are actively implementing a range of strategic initiatives, including mergers and acquisitions, partnerships, and collaborative agreements, to strengthen their regional footprint and enhance the marketing and distribution of their product portfolios. These strategies are aimed at not only expanding their geographic presence but also improving accessibility and adoption of advanced solutions in diverse healthcare markets.

For instance, in September 2021, Terumo Corporation announced the launch of PANTHER, a global surgical graft study. This extensive study is designed to be both retrospective and prospective in nature, covering a broad spectrum of knitted and woven surgical grafts, as well as cardiovascular patches. The study underscores Terumo’s commitment to clinical innovation and evidence-based research, with the goal of improving surgical outcomes and broadening the clinical applications of its graft and patch products.

Similarly, in February 2020, CorMatrix Cardiovascular, Inc. revealed that it had received FDA approval to enroll 20 additional patients and expand the adult arm of its feasibility study on the Cor TRICUSPID ECM valve. This study includes both adult and pediatric patients, highlighting the company’s efforts to advance regenerative cardiovascular therapies across different age groups. The approval reflects the growing confidence in ECM-based technologies and supports CorMatrix’s long-term objective of developing safe and effective solutions for tricuspid valve repair and replacement.

Key Players

• Cook Group

• Coloplast Group

• Smith & Nephew

• Koninklijke DSM N.V.

• MTF Biologics

• Boston Scientific Corporation

• Medtronic

• Baxter

• Aziyo Biologics

• Admedus Ltd.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The ECM patches market is expected to grow steadily, driven by higher incidence of cardiovascular and congenital conditions, increased trauma surgeries, and wider acceptance of ECM patches in reconstructive and soft tissue repair procedures. Key advantages of ECM over synthetic materials — such as improved biocompatibility, durability, and flexibility — are helping adoption. Regions with strong healthcare infrastructure lead the market now, while developing markets are expected to grow faster as awareness and investments increase. However, product cost and pricing remain barriers to wider uptake in lower-income areas.